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Introduction
 Breast cancer is not only the most common cancer 
among women throughout the world in developing and 
developed regions, but is also the most frequent cause 
of cancer death in women in developing and developed 
regions (Ferlay et al., 2010). A key determinant of breast 
cancer outcome is to detect breast cancer at the early stages 
(Yip et al., 2008). Early detection leads to a lower breast 
cancer mortality rate. Thus, many countries – at least 
22 – have established population-based breast screening 
programs using mammography (Shapiro et al., 1998).
 Many research publications demonstrate that 
mammography lowers breast cancer mortality by 25-30% 
(Shapiro et al., 1998). Currently, mammography is the 
gold standard for early screening of breast cancer (Yip et 
al., 2008) because mammography has proven successful 
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Abstract
 Background: Mammography is considered the gold standard of breast cancer mass screening and many 
countries have implemented this as an established breast cancer screening strategy. However, although the 
incidence of breast cancer and racial characteristics are different between Western and Asian countries, many 
Asian countries adopted mammography for mass screening. Therefore, the objective of this research was to 
determine whether mammography mass screening is cost-effective for both Western and Asian countries. 
Materials and Methods: A systematic review was performed of 17 national mammography cost-effectiveness 
data sets. Per capita gross domestic product (GDP), breast cancer incidence rate, and the most optimal cost-
effectiveness results [cost per life year saved (LYS)] of a mammography screening strategy for each data set 
were extracted. The CE/per capita GDP ratio is used to compare the cost-effectiveness of mammography by 
FRXQWULHV1RQSDUDPHWULFUHJUHVVLRQZDVXVHGWRÀQGDFXWRIISRLQWZKLFKLQGLFDWHGWKHEUHDVWFDQFHULQFLGHQFH
rate boundary line determining whether mammography screening is cost-effective or not. Results: We found 
that the cost-effective cut-off point of breast cancer incidence rate was 45.04; it exactly divided countries into 
Western and Asian countries (p<0.0014). Conclusions: Mammography screening is cost-effective in most of 
Western countries, but not in Asian countries. The reason for this result may be the issues of incidence rate or 
racial characteristics, such as dense breast tissue. The results indicate that mammography screening should be 
adopted prudently in Asian countries and other countries with low incidence rates. 
Keywords: Breast cancer - cost-effectiveness - mammography - mass screening - systematic review - Asia
RESEARCH ARTICLE
Is Mammography for Breast Cancer Screening Cost-Effective 
in Both Western and Asian Countries?: Results of a Systematic 
Review
Ki-Bong Yoo1,2, Jeoung A Kwon1,2, Eun Cho3, Moon Hae Kang1,2, Jung-Mo Nam4, 
Kui Son Choi5, Eun Kyung Kim6, Yun Jeong Choi7, Eun-Cheol Park2,4*
in early detection and good prognosis for breast cancers 
across the range of ages and mutation status (Maurice 
et al., 2012). As such, some Asian countries, including 
Korea (Kim et al., 2011), Japan (Kikuchi et al., 2012), 
China (Huang et al., 2001; Ma et al., 2012), and Taiwan 
(Huang et al., 2001; Leong et al., 2010), as well as many 
Western countries, including the US (White et al., 1990; 
USPSTF, 2009), Canada (Tonelli et al., 2011), the UK 
(Parkin et al., 2005; Evans et al., 2012), Norway (Lynge 
et al., 2011; Hofvind et al., 2012; Olsen et al., 2013), and 
The Netherlands (de Koning et al., 1995; Fracheboud et 
al., 1998), are implementing mammography for breast 
cancer screening and they expect lower mortality as well as 
cost-effectiveness, but the cost-effectiveness was unclear 
(Kikuchi et al., 2012).
 The factors of age, breast tissue density, history 
of breast biopsy, family history of breast cancer, and 
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screening interval must be considered for a mammography 
screening strategy (Schousboe et al., 2011). However, 
Mammography for breast cancer mass screening has 
been applied around the world even though there is much 
variability between Asian and Western countries. An 
Asian mammography screening program should consider 
cultural, and educational barriers prior to developing a 
screening program for breast cancer (Green and Raina, 
2008).
 The incidence rates of breast cancer in women with 
age-adjusted as reported by the OECD in 2008 showed a 
wide range, with The Netherlands having the highest rate 
at 98.5 per 100,000 people and China having the lowest 
at 21.6 per 100,000 people (Ferlay et al., 2010). While 
the incidence rates of breast cancer in North America and 
the European Union are 76 and 77.1 per 100,000 people, 
respectively, incidence rates in Asian countries is 26 per 
100,000 people (Ferlay et al., 2010). In addition, because a 
larger proportion of Asian women have dense breast tissue 
compared to Western women (El-Bastawissi et al., 2001), 
the accuracy of mammography could be reduced. The risk 
for breast cancer is four to six times higher in women 
with dense breasts. Breast density may also decrease the 
VHQVLWLYLW\VSHFLÀFLW\DQGLQFUHDVHERWKIDOVHSRVLWLYHDQG
false-negative mammography. Radiographically dense 
breast tissue may also obscure tumors, which increases 
WKHGLIÀFXOW\RIGHWHFWLQJEUHDVWFDQFHU,QDGGLWLRQGHQVH
breast tissue may mimic breast cancer on mammography, 
ZKLFK LQFUHDVHV UHFDOO UDWHV UHGXFHV VSHFLÀFLW\ DQG
FRPSURPLVHV WKH EHQHÀW RI VFUHHQLQJ LQZRPHQZLWK
dense breasts such as women who use HRT or who are 
premenopausal (Carney et al., 2003).
 Because the incidence rates of breast cancer and 
dense breast rate are different for each country, especially 
Western and Asian countries, there is a need to review 
the cost-effectiveness of mammography screening for 
breast cancer. Therefore, this study aims to compare 
the cost-effectiveness of mammography screening in 
different incidence rate of Western and Asian countries by 
systematic review. The CE/per capita GDP ratio is used 
to compare the cost-effectiveness of mammography by 
countries. It is calculated by (Cost per LYS of each of the 
screening strategies/per capita GDP of the corresponding 
country). The CE/per capita GDP ratio is proposed by 
the WHO Commission on Macroeconomics and Health 
(WHO, 2001).
 
Materials and Methods
Search strategy
 This study is a systematic review. Ovid-Medline, 
Ovid-Embase, and Cochrane Library database from 1974 
to June 25, 2012 were used.
 Advanced search and “Exploding” a search term for 
retrieving all records with not only the exact term, but 
also those in the hierarchy of the medical subject headings 
(MESH) were used. The search formula was: (breast 
cancer.mp. OR exp breast cancer/OR exp breast neoplasms 
OR mass screening.mp. OR exp mass screening/) AND 
(exp mammography/OR exp digital mammography/OR 
mammography.mp.) AND (cost-effectiveness.mp. OR exp 
cost-effectiveness analysis/). Additionally, references of 
articles were searched and a hand search was conducted.
Selection criteria
 Original articles published in English regarding breast 
cancer, mammography screening, and cost-effectiveness 
analysis of a screening strategy compared with no 
screening are included. Cost per life year saved (LYS), 
cost per quality adjusted life year (QALY), and cost per 
disability adjusted life year (DALY) averted were included 
in the scope of cost-effectiveness analysis. Additionally, 
this research included a result from a national report which 
is supported by the National R&D Program for Cancer 
Control, Ministry of Health and Welfare, Republic of 
Korea, which also supports the research presented here.
Extracted information
 Two researchers reviewed the abstract first in 
accordance with the inclusion criteria independently and 
reviewed the full selected articles. Extracted information 
was study objective, type of model, cost inclusion, country, 
study period, reference year of incidence, reference year of 
cost, screening strategy (age, interval), and cost per LYS. 
If the cost per LYS was not used, cost per DALY averted 
or cost per QALY were included. Cost-effectiveness 
analysis between mammography and no screening was 
selected. If the results of the cost-effectiveness analysis 
were divided into sub-groups for each screening interval 
and age group, the most optimal cost-effectiveness result 
of the article was selected for statistical analysis.
 Cost per LYS was converted into US dollars on the 
reference year of cost of each article. Per capita gross 
domestic product (GDP) corresponded with the study 
country, and the cost reference year of each article was 
retrieved from the World Bank to adjust for each countries 
characteristics (The World Bank, 2013). In the guidelines 
proposed by the WHO Commission on Macroeconomics 
and Health (WHO, 2001), the CE (cost-effectiveness)/
SHUFDSLWD*'3UDWLR LVGHÀQHGDV WKHUDWLRRIFRVWSHU
LYS and per capita GDP. This ratio was computed to 
determine cost-effectiveness of mammography and to 
compare this value with each country’s cost effectiveness 
result while also considering time-period effects. The 
discount rate was not considered in calculating the cost 
effectiveness, because this study calculated each country’s 
cost effectiveness with the ratio. 
 Breast cancer incidence rates were retrieved from 
GLOBOCAN 2008 and IARC CI5 plus, which includes 
data up to the year 2002 (Ferlay et al., 2010; IARC, 2011). 
Each article’s incidence rate was selected by reference 
year of incidence and mean of incidence rate during the 
study period was used as an incidence rate. For the period 
of 2003-2007, for which there is no data in GLOBOCAN 
or CI5 plus, the incidence rate was projected by simple 
interpolation.
Quality criteria
 For assessment of article quality, two researchers 
independently used the Quality of Health Economic 
Studies (QHES) instrument and came to an agreement 
after having assessed the tool (Ofman et al., 2003) (Table 
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1). The QHES tool was composed of a total of 16 criteria, 
with each of the criteria to be answered with either “yes” 
or “no.” Points ranging from 1 to 9 were allocated for each 
of the items. Full points were given for each item if the 
answer was “yes” and 0 points were given if the answer 
was “no.” Total score was 100 points.
Statistical analysis
 After collecting the cost per LYS data from selected 
DUWLFOHV VWDWLVWLFDO DQDO\VHVZHUHFRQGXFWHG WRÀQGRXW
the cut-off point of incidence to divide countries based 
on whether the mammography mass screening is cost-
effective or not.
 The analysis was determined with the weighted value 
of the quality assessment on the CE/per capita GDP ratio 
as the dependent variable. The QHES results by each study 
were various, so the weighted ratio was used to adjust 
for the quality of each study. We have included both the 
unweighted CE/per capita GDP ratio and the weighted one 
in the analysis model. Non-parametric statistical methods 
were used because the CE/per capita GDP ratio data are 
skewed and the number of articles is small. 
 Non-parametric regression (GAM procedure) that 
ÀWVJHQHUDOL]HGDGGLWLYHPRGHOVZDVXVHG WRGHWHUPLQH
incidence rate cut-off points, which indicate the CE/per 
capita GDP ratio is 1. This is similar to normal regression 
but can be used when the dependent variable is not 
normally distributed or the data is not the assumed linear 
(Hardle, 1990). The dependent variable is the logged 
CE/per capita GDP and the independent variable is the 
incidence rate.
 Differences in the CE/per capita GDP ratios between 
WKHWZRJURXSVZHUHFRQÀUPHGWKURXJK:LOFR[RQ5DQN
Sum Test by dividing the subject into two groups on the 
basis of the deduced cut-off point by non-parametric 
regression. In the case of district, differences in the CE/
SHUFDSLWD*'3UDWLRVZHUHFRQÀUPHGWKURXJK.UXVNDO
Wallis analysis by dividing the district into three groups, 
namely, Asia, Europe, and the US. The statistical test was 
performed using SAS, version 9.2.
Results 
Search results
 A total of 907 papers were searched, and among 
these, abstracts of 677 papers, after having excluded 230 
repetitive papers based on a selective withdrawal standard, 
were reviewed independently by two researchers. Three 
overseas papers were additionally selected through a 
hand-search, along with one article from Korea that 
was funded by the National R&D Program for Cancer 
Control, Ministry of Health and Welfare in the Republic of 
Korea. A total of 16 papers were selected and 17 national 
data sets extracted from the selected papers (Figure 1). 
Full articles of the selected studies were independently 
reviewed by two researchers. The reasons for excluding 
the remaining articles were: study type other than a cost-
effectiveness study, no comparison with a no-screening 
test, and duplicate publication.
Mammography cost-effectiveness literature review
 Results of the literature review on mammography cost-
HIIHFWLYHQHVVDUHVXPPDUL]HGLQ7DEOH7KHWRWDOQXPEHU
of selected studies was 16 with a total of 17 national data 
sets deduced from the studies, including 5 from the US, 
7 from Asian countries, and 6 from the European Union. 
 (DFKVWXG\SHULRGDPRQJHDFKVWXG\ZDVGHÀQHGDV
the duration of simulation or data used. The reference 
year of incidence indicates the year of incidence data in 
each study. The reference year of cost indicates the year 
of cost data in each study. 
 Among 16 studies, 11 studies (de Koning et al., 1991; 
*DUX]HWDO9DQGHU0DDVHWDO5RVHQTXLVW
and Lindfors, 1998; Stout et al., 2006; Woo et al., 2007; 
Okonkwo et al., 2008; de Gelder et al., 2009; Wong et 
al., 2010; Carles et al., 2011; Schousboe et al., 2011) 
Table 1. The Quality of Health Economic Studies (QHES) Instrument
Questions Points Yes No
 :DVWKHVWXG\REMHFWLYHSUHVHQWHGLQDFOHDUVSHFLÀFDQGPHDVXUDEOHPDQQHU" 
 :HUHWKHSHUVSHFWLYHRIWKHDQDO\VLVVRFLHWDOWKLUGSDUW\SD\HUHWFDQGUHDVRQVIRULWVVHOHFWLRQVWDWHG" 
3. Were variable estimates used in the analysis from the best available source  8
 LHUDQGRPL]HGFRQWUROWULDOEHVWH[SHUWRSLQLRQZRUVW"
 ,IHVWLPDWHVFDPHIURPDVXEJURXSDQDO\VLVZHUHWKHJURXSVSUHVSHFLÀHGDWWKHEHJLQQLQJRIWKHVWXG\" 
5. Was uncertainty handled by (1) statistical analysis to address random events,   9
 VHQVLWLYLW\DQDO\VLVWRFRYHUDUDQJHRIDVVXPSWLRQV"
 :DVLQFUHPHQWDODQDO\VLVSHUIRUPHGEHWZHHQDOWHUQDWLYHVIRUUHVRXUFHVDQGFRVWV" 
 :DVWKHPHWKRGRORJ\IRUGDWDDEVWUDFWLRQLQFOXGLQJWKHYDOXHRIKHDOWKVWDWHVDQGRWKHUEHQHÀWVVWDWHG" 
 'LGWKHDQDO\WLFKRUL]RQDOORZWLPHIRUDOOUHOHYDQWDQGLPSRUWDQWRXWFRPHV" 
 :HUHEHQHÀWVDQGFRVWVWKDWZHQWEH\RQG\HDUGLVFRXQWHGWRDQGMXVWLÀFDWLRQJLYHQIRUWKHGLVFRXQWUDWH"
 :DVWKHPHDVXUHPHQWRIFRVWVDSSURSULDWHDQGWKHPHWKRGRORJ\IRUWKHHVWLPDWLRQRITXDQWLWLHVDQGXQLWFRVWVFOHDUO\GHVFULEHG" 
10. Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major short-term  6
 ZDVMXVWLÀFDWLRQJLYHQIRUWKHPHDVXUHVVFDOHVXVHG"
:HUHWKHKHDOWKRXWFRPHVPHDVXUHVVFDOHVYDOLGDQGUHOLDEOH",ISUHYLRXVO\WHVWHGYDOLGDQGUHOLDEOHPHDVXUHVZHUHQRWDYDLODEOH
 ZDVMXVWLÀFDWLRQJLYHQIRUWKHPHDVXUHVVFDOHVXVHG"
12. Were the economic model (including structure), study methods and analysis, and the components of the numerator and  8
 GHQRPLQDWRUGLVSOD\HGLQDFOHDUWUDQVSDUHQWPDQQHU"
:HUHWKHFKRLFHRIHFRQRPLFPRGHOPDLQDVVXPSWLRQVDQGOLPLWDWLRQVRIWKHVWXG\VWDWHGDQGMXVWLÀHG" 
'LGWKHDXWKRUVH[SOLFLWO\GLVFXVVGLUHFWLRQDQGPDJQLWXGHRISRWHQWLDOELDVHV" 
:HUHWKHFRQFOXVLRQVUHFRPPHQGDWLRQVRIWKHVWXG\MXVWLÀHGDQGEDVHGRQWKHVWXG\UHVXOWV" 
:DVWKHUHDVWDWHPHQWGLVFORVLQJWKHVRXUFHRIIXQGLQJIRUWKHVWXG\" 
 Total Points 100
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DQDO\]HGWKHYDULRXVUDQJHRIWKHDJHJURXSVDQGLQWHUYDOV
of scenarios. The other 5 studies (Knox, 1988; Okubo et 
al., 1991; Leivo et al., 1999; Norum, 1999; Kang et al., 
DQDO\]HGDVLQJOHVFUHHQLQJVWUDWHJ\5HVHDUFKRQ
the cost-effectiveness of a single screening strategy, with 
WKH H[FHSWLRQ RI -DSDQ 2NXER HW DO  DQDO\]HG
the mammography screening strategy that was being 
implemented in the corresponding country at that time.
 In Schousboe et al.’s (2011) study, the cost per LYS 
was reduced even further as age increased under the same 
intervals. According to Stout et al. (2006), the cost per 
LYS decreased as the screening interval increased when 
compared with the cost per LYS of screening intervals of 1, 
2, and 3 years for the age group of 45-75 years. Woo et al. 
(2007) illustrated that the cost per LYS decreased when the 
screening interval was increased. The same phenomenon 
ZDVIRXQGLQRWKHUVWXGLHV9DQGHU0DDVHWDOGH
Koning et al., 1991; Carles et al., 2011). In addition, the 
cost per LYS decreased when the screening age group was 
reduced from 40~74 to 50~74 under the same screening 
LQWHUYDO7KLVZDV IRXQG WREH WKHFDVH LQ*DUX]HW DO
(1997), de Koning et al. (1991), and Okonkwo et al. (2008) 
studies. In the research by Wong et al. (2010), when the 
US was compared with China, there were differences in 
the cost-effectiveness under the same screening interval 
and screening age group.
 5HVHDUFKE\GH*HOGHU HW DO  VRXJKW WRÀQG
an appropriate mammography screening strategy by 
FRPELQLQJ WKH RSSRUWXQLVWLF VFUHHQLQJ DQG RUJDQL]HG
VFUHHQLQJRIPDPPRJUDSK\,Q6ZLW]HUODQGRSSRUWXQLVWLF
VFUHHQLQJDQGRUJDQL]HGVFUHHQLQJDUHEHLQJFRPELQHG
for application on mammography for each of the cantons. 
Rosenquist et al. (1998) sought to re-appraise the cost-
effectiveness of mammography screening in the 40-49 
years of age group.
Quality criteria
 Overall average quality assessment score was 82.1. 
For questions 1, 8, 10, and 15, the proportion of “yes” as 
the answer was 100% in all studies. The question with the 
lowest proportion of “yes” answers was question 11, at 
11.8%. In the majority of the literature, it was found that 
aspects on the health outcome following mammography 
are insufficient. Questions 6 and 7 had the second 
lowest “yes” answers, at 58.8%. Question 6 was on the 
incremental analysis performed between alternatives for 
resources, while 7 studies did not carry out studies on these 
aspects and 7 studies did not mention data abstraction, 
which is question 7.
Incidence rate cut-off point to determine cost-effectiveness 
of mammography
 Incidence rates and mortality rate of breast cancer for 
each study were retrieved from CI5 plus and GLOBOCAN Figure 1. Summary of the Literature Search
Excluded duplicate studies 
and data (n = 677) 
Excluded: duplicated studies and data   
(n = 230) 
Added: hand search (n = 4) 
Total searched studies (n = 903)  Search results by strategy (n = 907) 
Excluded: not published in English 
(n = 55) 
Published in English 
(n = 622) 
Excluded: not original studies  
(n = 84)  
Original studies 
(n = 538) 
Excluded: not breast cancer studies 
(n = 68) 
Breast cancer studies 
(n = 470) 
Excluded: not mammography studies  
(n = 153) 
Mammography studies 
(n = 317) 
Excluded: not cost-effectiveness analysis  
(n = 249) 
Cost-effectiveness analysis 
(n = 68) 
Excluded: not compared with no-screening 
studies (n = 52) 
Selected studies (n = 16) 
Selected data     (n = 17) Total exclusion studies (n = 891) Total inclusion studies (n = 16) 
Total inclusion data (n = 17) 
Table 3. Incidence Rate, Mortality Rate of Breast Cancer and Per-Capita GDP for Each Study
Country References Incidence Mortality Per-capita  Cost (US$) per  CE/per capita  Logged CE/per capita
  rate* rate* GDP (US$) (a) LYS or QALY (b) GDP ratio (b/a) GDP ratio predictions**
India Okonkwo et al., 2008 26.1 11.1 460 3,308 7.19 0.46
Japan Okubo et al., 1991 26.2 6 16,882 14,300 0.85 0.50
China Wong et al., 2010 28.5 5.8 1,731 64,400 37.20 1.42
China Woo et al., 2007 35.8 5.9 1,042 90,771 87.10 1.69
South Korea Kang et al., 2013 38.9 5 16,959 29,964 1.77 0.50
Spain Carles et al., 2011 53.6 15.8 26,056 4,691 0.18 -0.69
UK Knox, 1988 55.4 27.4 10,064 3,730 0.37 -0.51
6SDLQ *DUX]HWDO      
Finland Leivo et al., 1999 70.8 16.6 25,609 18,955 0.74 -0.29
7KH1HWKHUODQGV 9DQGHU0DDVHWDO      
Norway Norum, 1999 72.6 19.7 36,555 14,554 0.40 -0.45
The Netherlands de Koning et al., 1991 74.2 27.1 16,116 3,235 0.20 -0.51
6ZLW]HUODQG GH*HOGHUHWDO      
US Rosenquist and Lindfors, 1998 77.4 22 16,539 16,100 0.97 -0.25
US Woo et al., 2007 81.2 15.3 42,516 37,000 0.87 -0.05
US Stout et al., 2006 84 21 35,082 27,000 0.77 -0.04
US Schousboe et al., 2011 84.1 20.1 46,760 48,884 1.05 -0.04
$JHVWDQGDUGL]HGUDWHVSHUIHPDOHV5HVXOWVIURPQRQSDUDPHWULFUHJUHVVLRQWHVW0RGHOVLJQLÀFDQFHS') 
Search results by strategy 
( 907
Exclude  uplicate studies and data
(n=677)
Published  glish
(n=622)
Origin l st ies
( 538)
Breast can dies
(n=470)
Mam ogr  studies
( 317)
Cost-e!ecti e s analy is 
( 68)
Selected studies (n=16)
Sel cted at       (n=17)
Excluded: not compared with no-screening studies
(n=52)
Excluded: not cost-e!ectiveness analysis 
(n=249)
Excluded: not mammography studies 
(n=153)
Excluded: not breast cancer studies
(n=68)
Excluded: not original studies 
(n=84) 
Excluded: not published in English
(n=55)
Excluded: duplicated studies and data
(n=230)
Added: hand search
(n=4)
Total searched studies
(n=903)
Total exclusion studies (n=891)
al inclusion studies (n=16)
tal inclusion data (n=17)
Ki-Bong Yoo et al
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based on the each study’s reference year (Table 3). Per 
capita GDP was found through the World Bank on the 
basis of the reference year of cost of each study. The most 
cost-effective values in each of the studies were selected 
as the representative values for cost per LYS or QALY. 
In addition, the CE/per capita GDP ratio was computed 
by dividing cost per LYS or QALY by per capita GDP. In 
the case of research by Schousboe et al. (2011), average 
cost per LYS of all screening strategies was used as a 
representative value, because the result was for the same 
screening strategy. 
 We displayed the result of execution of non-parametric 
UHJUHVVLRQWRÀQGWKHFXWRIISRLQWVRILQFLGHQFHUDWHLQ
Table 3. Logged CE/per capita GDP ratio predictions were 
generated by non-parametric regression. The value over 
0 means that the CE/per capita GDP ratio is more than 
 LW LV LQHIÀFLHQW7KHSUHGLFWHG YDOXHVZHUH FKDQJHG
from positive to negative number between South Korea 
to Spain. As our calculation, incidence rate cut-off was 
45.04 per 100,000 women with age-adjusted at the point 
ZKHUHWKH&(SHUFDSLWD*'3UDWLR 
 The difference between the two groups divided by 
WKHFDOFXODWHGFXWRII ZDVDQDO\]HGE\:LOFR[RQ
Rank Sum Test. With a p-value of 0.0003, statistically 
VLJQLÀFDQWUHVXOWVZHUHREWDLQHG7DEOH7KHDYHUDJH
CE/per capita GDP ratios of the two groups were 8.10 
and 0.51, thereby indicating a difference between the two 
groups. The countries that were on the borderline were 
.RUHDDQG6SDLQZKLFKZHUHFDWHJRUL]HGLQWR$VLDQDQG
Western countries, respectively (Figure 2). There were the 
same statistical results between the weighted p values and 
non-weighted p values. When the countries were divided 
into three groups, namely, Asia, the US, and Europe, the 
differences between the Europe-Asia, Europe-US, and 
$VLD86JURXSVZHUHVLJQLÀFDQW
Discussion
In this study, studies on the cost-effectiveness of 
mammography screening for the general population 
were reviewed systematically, and the differences in the 
cost-effectiveness of mammography screening between 
Western and Asian countries were also examined.
Sixteen studies were selected and the number of 
countries included in the analysis was 11. The quality of 
the study was assessed using QHES. QHES is useful for 
this study because it was developed to evaluate three main 
W\SHV RI KHDOWK HFRQRPLF DQDO\VLV FRVWPLQLPL]DWLRQ
cost-effectiveness, and cost-utility. The QHES tool 
has been formally validated and shown to be simple, 
consistent, and valid for measuring cost-effectiveness 
studies (Peterson et al., 2009). In general, a score of more 
than 70 is determined to be the cut-off for a “good-quality 
study” (Peterson et al., 2009). In this study, the average 
QHES of the literature was 82.1, and most of the studies 
can be considered good quality with QHES scores of 
more than 70.
To examine the differences in cost-effectiveness, 
a comparison was made using the CE/per capita GDP 
ratio. If the CE/per capita GDP ratio is more than 1, then 
PDPPRJUDSK\VFUHHQLQJFDQEHGHHPHGWREHLQHIÀFLHQW
because the cost per LYS exceeds the per capita GDP 
(WHO, 2001; Okonkwo et al., 2008). That is, it can be 
VDLGWREHLQHIÀFLHQWLIWKHFRVWRIVDYLQJRQHSHUVRQIRU
a period of 1 year is more than the total value a person 
generates in a year. The advantage of this method is that 
the differences for each year and the cost of goods can be 
adjusted because the computation is made in the form of 
a CE/per capita GDP ratio between per capita GDP and 
cost per LYS for the corresponding year, regardless of 
the diversity year for per capita GDP and cost per LYS.
Table 3 illustrates that it is not cost-effective in most 
Asian countries (Korea, China, and India) with the CE/
per capita GDP ratio of more than 1. In contrast, it is cost-
HIIHFWLYHLQ:HVWHUQFRXQWULHVWKH866SDLQ6ZLW]HUODQG
The Netherlands, the UK, Norway, and Finland), with the 
CE/per capita GDP ratio of less than 1. As an exception, 
Japan had the CE/per capita GDP ratio of approximately 
0.85 in contrast to the other Asian countries. The incidence 
rate of breast cancer in Japan is rapidly increasing and 
already has the highest incidence rate among all female 
cancers (Yip et al., 2008). It can be presumed that Japan 
is in a situation similar to Western countries such as the 
US, Norway, and the Netherlands. In the case of the US 
(Schousboe et al., 2011), the CE/per capita GDP ratio was 
computed to be 1.05 in a 2011 study. It can be interpreted 
that the cost per LYS of mammography in the US in 
comparison to the per capita GDP is higher than other 
countries. This is because the US population is consisted 
of more complex races; therefore, dense breast rate can 
be higher than other western countries. Also, the total 
medical cost of population in the US is relatively higher 
than other western countries.
As illustrated in Table 4, when the countries are 
Table 4. ,QÁXHQFH)DFWRUVRI&RVW(IIHFWLYHQHVV&XW
Off Point by Groups
 No. of  Incidence  Average CE/per  p value 
 studies rate‡ capita GDP ratio† (weighted)
Incidence rate†    
    
    
&RXQWULHV    
 Asia 5 30.5 8.1 Europe-Asia*
 Europe 8 66.5 0.35 Europe-US*
 US 4 81.6 0.91 Asia-US*
S†Cut-off point by non-parametric regression. ‡Geometric average
Figure 2. The CE Per Capita GDP Ratio by Incidence 
Rate
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divided into two groups, one including India (Okonkwo 
et al., 2008), Japan (Okubo et al., 1991), China (Woo et 
al., 2007; Wong et al., 2010), and Korea (Kang et al., 
2013), and the other including the UK (Knox, 1988), 
6SDLQ*DUX]HWDO&DUOHVHWDO)LQODQG
(Leivo et al., 1999), The Netherlands (Leivo et al., 
1RUZD\1RUXP6ZLW]HUODQGGH*HOGHU
et al., 2009), and the US (Lindfors and Rosenquist, 1995; 
Rosenquist and Lindfors, 1998; Stout et al., 2006; Wong 
et al., 2010; Schousboe et al., 2011) on the basis of the 
cut-off point of 45.04 for the incidence rates, there was 
DVWDWLVWLFDOO\VLJQLÀFDQWGLIIHUHQFHLQWKH&(SHUFDSLWD
*'3UDWLRVDQGWKHWZRJURXSVDUHGHÀQLWHO\GLYLGHGLQWR
Asian and Western countries. This illustrates that there 
is difference in the cost-effectiveness of breast cancer 
mammography screening between Asian countries such as 
India, Japan, China, and Korea with low incidence rates, 
and Western countries such as the UK, Spain, Finland, 
7KH1HWKHUODQGV1RUZD\ 6ZLW]HUODQG DQG WKH86
with relatively higher incidence rates. These differences 
HPSKDVL]HWKHQHHGIRUFRQVLGHUDWLRQRIWKHLQFLGHQFHUDWH
at the time of application of mammography screening. 
When the incidence rate of breast cancer is high, breast 
cancer is more likely to be detected by mammography; 
therefore, the more people can save life years compared 
to low incidence rates of breast cancer. If the cost of the 
mammography is the same, the cost per LYS decreases 
in countries with a high incidence rate of breast cancer. 
Such difference in the CE/per capita GDP ratios 
between Western and Asian countries can be deemed 
to be the result in the differences in incidence rates and 
breast tissue density. Although there is an increasing 
trend of incidence rates of breast cancer in both Asian 
and Western countries, incidence rates in Western 
countries are fundamentally higher than those of Asian 
countries (Leong et al., 2010). There may be a difference 
in the appearance of incidences of breast cancer between 
Western and Asian countries due to racial characteristics, 
geographic variation, racial/ethnic background, genetic 
variation, lifestyle, environmental factors, socioeconomic 
status, the presence of known risk factors, use of screening 
mammography, stage of disease at diagnosis, and the 
availability of appropriate care (Hortobagyi et al., 2005). 
For example, breast cancer in China showed more 
aggressive behavior than in Western countries – more 
LQYDVLYHGXFWDO FDUFLQRPDZLWK ODUJHU WXPRU VL]H ODWHU
stage, lower estrogen receptor and progesterone receptor 
expression, and higher human epidermal growth factor 
receptor 2 over expression than in Western countries 
(Zheng et al., 2012).
Differences of cost-effectiveness of breast cancer 
mammography between Asian and Western countries 
include the issue of dense breast tissue. The probability 
that Asian women have dense breast tissue is 2.1 times 
that of Caucasian women, and, when compared with other 
races, the ratio of dense breast tissue in Asian women was 
the highest (El-Bastawissi et al., 2001). Breast density may 
also decrease the sensitivity and, thus, the accuracy of 
mammography. The dense breast tissue appears white on 
DPDPPRJUDP6RLWFDQEHGLIÀFXOWWRUHFRJQL]HZKHWKHU
WKHZKLWHVKDGRZLVWXPRURUQRW,WLQFUHDVHVWKHGLIÀFXOW\
of detecting breast cancer (Graham-Rowe, 2012). The 
risk for breast cancer is four to six times higher in women 
with dense breasts. Therefore, dense breast tissue may 
LQFUHDVHUHFDOOUDWHVUHGXFHVSHFLÀFLW\DQGFRPSURPLVHV
WKHEHQHÀWVRI VFUHHQLQJ LQZRPHQZLWKGHQVHEUHDVWV
such as women who use HRT or who are premenopausal 
(Carney et al., 2003). As a result, the decreased accuracy 
of mammography leads to an increase in the risk of 
a false-positive result of breast cancer (Ohuchi et al., 
2009; Graham-Rowe, 2012). Therefore, there was an 
opinion in preceding research that the application of 
magnetic resonance imaging or ultrasonography should 
be recommended for Asians even though it is not yet 
included in the guidelines for all Asia countries (Ohuchi 
et al., 2009; Leung et al., 2010).
Some limitations are in this study. The total number of 
selected studies was 16 with a total of 17 national data sets 
deduced from the studies. The result should be interpreted 
carefully, because the small number of studies is included 
LQÀQDO DQDO\VLV7KHUH LV WKHPHDVXUHPHQW OLPLWDWLRQ
The used cost-effectiveness results were diverse. When 
the cost per LYS was not available, cost per QALY or 
cost per DALY averted were included. We could consider 
more confounders such as adjusting the various intervals, 
age groups and cost-effectiveness model. Even though 
the data source is the same, the results can vary by each 
simulation odel (Mandelblatt et al., 2009). In addition, 
even if policymakers measure the value of human life 
in dollars to simplify the situation, there are moral and 
ethical issues around measuring the value of human life 
in dollars. The quality of mammography can also vary by 
FRXQWU\+RZHYHUWKHVHQVLWLYLW\DQGVSHFLÀFLW\RIHDFK
study’s mammography were not adjusted because of a 
lack of this information.
This study compared the cost-effectiveness of 
mammography in Western and Asian countries for breast 
cancer screening by incidence rates. The results show 
that mammography mass screening is not cost-effective 
in Asian countries, unlike Western countries, due to breast 
cancer incidence rate and racial characteristics issues. 
The countries that have a low breast cancer incidence 
rate, such as Asian countries, should act prudently 
when implementing mammography as the reference test 
targeting the general population. Other screening methods 
such as clinical breast examination could be a possible 
alternative.
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